News
The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...
The drug licensing talks cover the development, production and sale of a targeted cancer therapy and other CSPC Pharma ...
AstraZeneca (AZ) and CSPC Pharmaceuticals Group have entered into a partnership worth up to $5.3bn to develop therapies for ...
Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...
The collaboration aims to advance the discovery and development of novel oral candidates.
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...
20hon MSN
Find insight on Regis Healthcare, CSPC Pharmaceutical and more in the latest Market Talks covering the health care sector.
The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...
AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.
Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results